Leo-pharma A/s

Patrick Stephen Johnson

Alan Stuart Jessiman

Kevin Neil Dack

Morten Dahl Sørensen

Mogens Larsen

Mark Andrews

Kristoffer Maansson

Xifu Liang

Peter Andersen

Lars Jørgensen

Krister Henriksson

Mia Nørreskov Burhardt

The present invention relates to a compound according to formula (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g., dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

Small molecule modulators of IL-17

The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

The present invention relates to a compound according to general formula (I) wherein X represents N or CH; Ris &#x2014;CN, (C-C)alkyl, (C-C)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C-C)cycloalkyl(C-C)alkyl, (3-7 membered)heterocycloalkyl-(C-C)alkyl or (5-6 membered)heteroaryl-(C-C)alkyl; Ris halogen, cyano, (C-C)alkyl or (C-C)cycloalkyl; Ris halogen, cyano, (C-C)alkyl, (C-C)haloalkyl or (C-C)cycloalkyl; Ris (C-C)alkyl or (C-C)haloalkyl; Ris (C-C)alkyl, (C-C)cycloalkyl, (C-C)alkyl-(C-C)cycloalkyl, (C-C)cycloalkyl-(C-C)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or &#x2014;OR. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds. 

Heteroaromatic modulators of the retinoid-related orphan receptor gamma

The present invention relates to a compound according to general formula (I) wherein X represents N or CH; Ris &#x2014;CN, (C-C)alkyl, (C-C)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C-C)cycloalkyl(C-C)alkyl, (3-7 membered)heterocycloalkyl-(C-C)alkyl or (5-6 membered)heteroaryl-(C-C)alkyl; Ris halogen, cyano, (C-C)alkyl or (C-C)cycloalkyl; Ris halogen, cyano, (C-C)alkyl, (C-C)haloalkyl or (C-C)cycloalkyl; Ris (C-C)alkyl or (C-C)haloalkyl; Ris (C-C)alkyl, (C-C)cycloalkyl, (C-C)alkyl-(C-C)cycloalkyl, (C-C)cycloalkyl-(C-C)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or &#x2014;OR. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds.

The present invention relates to a compound according to formula (I) wherein Ris selected from the group consisting of 5- and 6-membered heteroaryl, (C-C)alkyl, (C-C)cycloalkyl, (4-6)-membered heterocycloalkyl and phenyl; Ris selected from (C-C)alkyl and halo(C-C)alkyl; Ris selected from phenyl, 5-membered heteroaryl and 6-membered heteroaryl; Ris selected from hydrogen, halogen, (C-C)alkyl and halo(C-C)alkyl; Xis selected from CH, C(R) and N, Xis selected from CH and N; Y is selected from &#x2014;NH&#x2014; and &#x2014;O&#x2014;; m is 0 or 1; n is 0 or 1; L represents a bond, &#x2014;O&#x2014;, &#x2014;NH&#x2014; or &#x2014;N(R)&#x2014;; or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.

Growing community of inventors

Ballerup, Denmark

Patrick Stephen Johnson